Hypertension, Pulmonary
"Hypertension, Pulmonary" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Increased VASCULAR RESISTANCE in the PULMONARY CIRCULATION, usually secondary to HEART DISEASES or LUNG DISEASES.
Descriptor ID |
D006976
|
MeSH Number(s) |
C08.381.423
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Hypertension, Pulmonary".
Below are MeSH descriptors whose meaning is more specific than "Hypertension, Pulmonary".
This graph shows the total number of publications written about "Hypertension, Pulmonary" by people in this website by year, and whether "Hypertension, Pulmonary" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
1995 | 6 | 1 | 7 | 1996 | 7 | 1 | 8 | 1997 | 10 | 2 | 12 | 1998 | 19 | 2 | 21 | 1999 | 13 | 1 | 14 | 2000 | 9 | 2 | 11 | 2001 | 9 | 1 | 10 | 2002 | 14 | 3 | 17 | 2003 | 14 | 4 | 18 | 2004 | 21 | 1 | 22 | 2005 | 33 | 4 | 37 | 2006 | 20 | 6 | 26 | 2007 | 21 | 4 | 25 | 2008 | 22 | 2 | 24 | 2009 | 28 | 2 | 30 | 2010 | 24 | 6 | 30 | 2011 | 34 | 6 | 40 | 2012 | 33 | 6 | 39 | 2013 | 36 | 6 | 42 | 2014 | 33 | 5 | 38 | 2015 | 42 | 7 | 49 | 2016 | 42 | 3 | 45 | 2017 | 39 | 5 | 44 | 2018 | 31 | 3 | 34 | 2019 | 37 | 2 | 39 | 2020 | 44 | 5 | 49 | 2021 | 37 | 0 | 37 | 2022 | 35 | 1 | 36 | 2023 | 35 | 1 | 36 | 2024 | 25 | 6 | 31 | 2025 | 15 | 0 | 15 |
To return to the timeline, click here.
Below are the most recent publications written about "Hypertension, Pulmonary" by people in Profiles.
-
Robbins EW, Bradley K, Badesch D, Burger C, Chyboski AM, De Marco T, Hemnes AR, Lammi M, Mathai SC, Melendres-Groves L, Raza F, Sager J, Shlobin O, Thenappan T, Zamanian R, Runo J, Baird GL, Ventetuolo CE. Medication Nonadherence in Patients with Pulmonary Arterial Hypertension: The Pulmonary Hypertension Association Registry (PHAR). Ann Am Thorac Soc. 2025 Jun; 22(6):830-837.
-
Montani D, McLaughlin VV, Gibbs JSR, Gomberg-Maitland M, Hoeper MM, Preston IR, Souza R, Waxman AB, Escribano Subias P, Feldman J, Meyer GM, Olsson KM, Coulet F, Manimaran S, Zhao Y, Lau A, de Oliveira Pena J, Badesch DB, Humbert M. Consistent Safety and Efficacy of Sotatercept for Pulmonary Arterial Hypertension in BMPR2 Mutation Carriers and Noncarriers: A Planned Analysis of a Phase II, Double-Blind, Placebo-controlled Clinical Trial (PULSAR). Am J Respir Crit Care Med. 2025 Jun; 211(6):1028-1037.
-
Shoaibi A, Ostropolets A, Weaver J, Rao GA, Golozar A, Swerdel J, Huser V, Adam A, Alshammari T, Anikpezie N, Baumgartner WA, Brand M, Fan R, Kanter AS, Kern D, Melisa S, Minty E, Mo J, Oluwalade B, Schilling LM, Spence H, Stocking JC, Zhang L, Ryan P. Variation in Phenotype Definitions in Observational Clinical Research: A Review of Three Conditions. AMIA Annu Symp Proc. 2024; 2024:1021-1029.
-
Lewis CV, Nguyen TN, Porfilio TE, Burciaga SD, Posey JN, Jordan M, Colon Hidalgo D, Stenmark KR, Mickael C, Sul C, Oberley-Deegan RE, Delaney C, Nozik ES. Vascular EC-SOD limits the accumulation, proinflammatory profibrotic reprogramming, and hyaluronan binding of interstitial macrophages in hypoxia. Am J Physiol Lung Cell Mol Physiol. 2025 Jun 01; 328(6):L885-L900.
-
Hoeper MM, Gomberg-Maitland M, Badesch DB, Gibbs JSR, Gr?nig E, Kopec G, McLaughlin VV, Meyer G, Olsson KM, Preston IR, Rosenkranz S, Souza R, Waxman AB, Perchenet L, Strait J, Xing A, Manimaran S, Wang X, Miller B, Cornell AG, de Oliveira Pena J, Ghofrani HA, Humbert M. Efficacy and safety of the activin signalling inhibitor, sotatercept, in a pooled analysis of PULSAR and STELLAR studies. Eur Respir J. 2025 May; 65(5).
-
Vijayakumar S, Louis DW, Corneau E, Erqou S, Waldo SW, Plomondon ME, Gokhale M, Sheikh W, Has P, Marwan S, Abbott JD, Jankowich M, Aronow HD, Wu WC, Choudhary G. Association between pre-existing Pulmonary Hypertension and COVID-19 related outcomes in inpatient and ambulatory care settings. PLoS One. 2025; 20(4):e0321964.
-
Yegambaram M, Pokharel MD, Sun X, Lu Q, Soto J, Aggarwal S, Maltepe E, Fineman JR, Wang T, Black SM. Restoration of pp60Src Re-Establishes Electron Transport Chain Complex I Activity in Pulmonary Hypertensive Endothelial Cells. Int J Mol Sci. 2025 Apr 17; 26(8).
-
Posey JN, Jordan M, Lewis CV, Sul C, Dobrinskikh E, Swindle D, Denorme F, Irwin D, Di Paola J, Stenmark K, Nozik ES, Delaney C. Nbeal2 knockout mice are not protected against hypoxia-induced pulmonary vascular remodeling and pulmonary hypertension. Blood Adv. 2025 Apr 08; 9(7):1571-1584.
-
Cookson MW, Gonzalez T, Bye EM, Seedorf G, Ellor S, Smith BJ, Fleet JC, Mandell EW. Intraamniotic vitamin D preserves lung development and prevents pulmonary hypertension in experimental bronchopulmonary dysplasia due to intraamniotic sFlt-1. Am J Physiol Lung Cell Mol Physiol. 2025 Apr 01; 328(4):L603-L615.
-
Gu S, Kopecky BJ, Pe?a B, Vagnozzi RJ, Lahm T. Sex-dependent Pathophysiology and Therapeutic Considerations in Right Heart Disease. Can J Cardiol. 2025 Jun; 41(6):1038-1053.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|